Biogen (BIIB) Cash from Financing Activities (2009 - 2026)

Biogen's Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$43.8 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 90.43% year-over-year to -$43.8 million; the TTM figure through Mar 2026 stood at -$322.7 million (down 20.91% YoY), while the FY2025 annual figure was -$301.9 million, up 55.83% from the prior year.
• Cash from Financing Activities was -$43.8 million for Q1 2026 at Biogen, up from -$137.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $848.6 million in Q3 2023 to a low of -$1.3 billion in Q3 2022.
• Historically, Cash from Financing Activities has averaged -$154.5 million across 5 years, with a median of -$43.4 million in 2023.
• Biggest YoY gain for Cash from Financing Activities was 167.78% in 2023; the steepest drop was 8631.08% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at -$7.4 million in 2022, then sank by 8631.08% to -$646.1 million in 2023, then soared by 101.22% to $7.9 million in 2024, then sank by 1834.18% to -$137.0 million in 2025, then jumped by 68.03% to -$43.8 million in 2026.
• The last three Cash from Financing Activities figures came in at -$43.8 million (Q1 2026), -$137.0 million (Q4 2025), and -$130.2 million (Q3 2025), per Business Quant data.